Hong Kong stock anomaly | Kangfang Biotechnology (09926.HK) opened nearly 5% higher, with first-half revenue increasing by nearly 40% year-on-year. The Evolocumab monoclonal antibody HARMONi-A study has reached the OS endpoint.
According to Zhixin Financial APP, Kangfang Biotech (09926.HK) opened nearly 5% higher, as of the time of writing, it has increased by 4.73% to HK$177, with a trading volume of HK$381 million.
Latest
